China-based RNA therapeutics developer Ribopeutic has raised close to 100 million yuan ($13.9 million) in pre-A financing, ...

Shares of Israel-based Nasus Pharma rose 7.6% to $8.88 in after-hours activity yesterday after it announced the pricing of ...

US biotech Response Pharmaceuticals (Nasdaq: RSPN) has unveiled top-line Phase II results for its experimental obesity ...

Danish CNS specialist Lundbeck has reported revenue grew 14% at constant exchange rates (CER), plus 14% DKK, to 12,258 ...

Maryland, USA-based biotech MacroGenics announced that effective as of August 13, 2025, Eric Risser has been appointed ...

China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, ...

Clustered regularly interspaced short palindromic repeats (CRISPR)-based therapeutics are rapidly gaining traction for the ...

Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately ...

Artificial intelligence is showing promise in improving the detection and management of idiopathic pulmonary fibrosis (IPF), ...

A voluntary rebate pilot for the 340B drug discount program is drawing attention as a potential way to address concerns over ...

US biotech Vedanta Biosciences has abandoned development of its ulcerative colitis candidate VE202 after the bacterial cocktail failed to outperform placebo in a mid-stage trial.